EATG » R&D

R&D

Funding for TB research falls to lowest level in seven years

LIVERPOOL, UNITED KINGDOM, OCTOBER 25, 2016 —Tuberculosis (TB) killed 1.8 million people in 2015, making it the most deadly infectious disease worldwide, but funding for research into better TB prevention,…

A decade of flat funding could imperil progress of the HIV prevention research pipeline

Report released at HIV Research for Prevention Conference highlights funding trends, opportunities and challenges for HIV prevention R&D CHICAGO, Oct. 19, 2016 -- A new report released today at the second…

U.N. High Level Panel on Access to Medicines releases final report

United Nations Secretary-General’s High-Level Panel on Access to Medicines calls for new deal to close the health innovation and access gap The High-Level Panel on Access to Medicines released today…

MSF urges governments to set medical research policies that align with people’s health needs

New MSF report exposes pharma industry failings and highlights new ways of researching and developing medicines that address public health needs Geneva, 14 September, 2016 – Governments must do more…

GlaxoSmithKline Is Working on a Much Simpler HIV Treatment

While there have been quite a good number of patients on Tivicay® (dolutegravir) already, and some even see it as a revolutionary next step in treatment and the simplification of…

First review of EmERGE closed with positive opinion

The EATG has been working in the EmERGE project as the lead for the Dissemination and Popularisation Work Package. EmERGE will develop an mHealth (mobile health = health related services…

Switch from TDF to TAF improves kidney and bone markers

The Body reports: Proteinuria, albuminuria and bone mineral density (BMD) improved significantly in HIV-positive people with mild or moderate renal impairment who switched to once-daily coformulated elvitegravir, cobicistat, emtricitabine and tenofovir…

Matthias Wienold on BMJ Blogs – New tools for participation in research

Founding EATG member and researcher of patient involvement and participation in clinical trials and medicines development, Matthias Wienold not only serves as IAPO Board member but has been blogging for…

The European AIDS Treatment News (EATN) complete collection 1992 – 2001 is now available

The EATG published the European AIDS Treatment News (EATN) for 10 years. This “newsletter” disseminated information for expert patients and treatment activists working across Europe. It contained the latest about medicines development, clinical…

EUPATI public consultation continues

The fourth framework of guidance regarding “patient involvement in the ethical review of clinical trials” has now been added to the EUPATI public consultation and all members are invited to…